In last trading session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) saw 1.42 million shares changing hands with its beta currently measuring 1.35. Company’s recent per share price level of $5.96 trading at $0.3 or 5.30% at ring of the bell on the day assigns it a market valuation of $345.88M. That closing price of DNA’s stock is at a discount of -698.66% from its 52-week high price of $47.60 and is indicating a premium of 11.74% from its 52-week low price of $5.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.25 million shares which gives us an average trading volume of 1.66 million if we extend that period to 3-months.
For Ginkgo Bioworks Holdings Inc (DNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.83. Splitting up the data highlights that, out of 5 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Upright in the green during last session for gaining 5.30%, in the last five days DNA remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $5.96 price level, adding 12.48% to its value on the day. Ginkgo Bioworks Holdings Inc’s shares saw a change of -39.31% in year-to-date performance and have moved -10.38% in past 5-day. Ginkgo Bioworks Holdings Inc (NYSE:DNA) showed a performance of -26.60% in past 30-days. Number of shares sold short was 9.98 million shares which calculate 4.85 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a rise of 8.31% to its current value. Analysts have been projecting 4.35 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would jump 27.01% in reaching the projected high whereas dropping to the targeted low would mean a gain of 27.01% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -27.97% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.93% while estimates for its earnings growth in next 5 years are of 48.92%.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Insiders are in possession of 6.59% of company’s total shares while institution are holding 79.82 percent of that, with stock having share float percentage of 85.46%. Investors also watch the number of corporate investors in a company very closely, which is 79.82% institutions for Ginkgo Bioworks Holdings Inc that are currently holding shares of the company. VIKING GLOBAL INVESTORS LP is the top institutional holder at DNA for having 143.09 million shares of worth $47.83 million. And as of 2024-06-30, it was holding 6.9686 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 138.96 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9327 of outstanding shares, having a total worth of $46.46 million.
